Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 9/20 | 0.66 |
| ▸ | GRPR | P30550 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 5/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30946722 | 0.97 | PTH1R (0.66) | PTH1RGRPRCXCR4RXFP1GLP1R | |
| SCHEMBL29412274 | 0.91 | GLP1R (0.73) | PTH1RGRPRRXFP1GLP1RNR3C1 | |
| SCHEMBL29774757 | 0.91 | GRPR (0.66) | PTH1RGRPRCXCR4RXFP1GLP1R | |
| SCHEMBL30408986 | 0.90 | PTH1R (0.67) | PTH1RGRPRCXCR4RXFP1GLP1R | |
| SCHEMBL31140800 | 0.90 | GLP1R (0.70) | PTH1RRXFP1GLP1RNR3C1ECE1 | |
| SCHEMBL29736864 | 0.90 | NR3C1 (0.72) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL29491080 | 0.89 | NR3C1 (0.76) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL29736869 | 0.87 | NR3C1 (0.72) | GRPRGLP1RNR3C1ECE1MUS81 | |
| SCHEMBL30744286 | 0.87 | NR3C1 (0.71) | PTH1RGRPRRXFP1GLP1RNR3C1 | |
| SCHEMBL30744278 | 0.87 | GRPR (0.69) | PTH1RGRPRCXCR4RXFP1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633680-A1 | THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-113286820-B | Methods and compounds for targeting sortilin receptors and inhibiting angiogenesis mimicry | 特拉斯福特普拉斯公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-118772291-A | Acidic surface-assisted dissolution short peptide tag for improving recombinant protein expression efficiency | 宜明（济南）生物科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240226128-A1 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | UNIVERSITY OF SHARJAH (AE) | 2024-07-11 | — | — | US | disclosed |
| CN-116496365-B | Acidic surface-assisted dissolution short peptide tag for improving recombinant protein expression efficiency | 宜明（济南）生物科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024129497-A1 | THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024119434-A1 | SOLUBILIZATION-ASSISTING SHORT PEPTIDE TAG WITH ACIDIC SURFACE FOR IMPROVING EXPRESSION EFFICIENCY OF RECOMBINANT PROTEIN | 宜明（济南）生物科技有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-11786537-B2 | Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2 | KING ABDULAZIZ UNIVERSITY (SA) | 2023-10-17 | — | — | US | disclosed |
| US-20230255981-A1 | THERAPEUTIC INHIBITION AFFINITY OF COPPER (II) COMPLEX AND THEIR DIAZENYL PYRIDINONE HETEROCYCLIC LIGANDS AGAINST SARS-COV2 | KING ABDULAZIZ UNIVERSITY (SA) | 2023-08-17 | — | — | US | disclosed |
| US-11723932-B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-107629129-B | Method for producing and purifying polypeptides | 清华大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-116496365-A | Acidic surface-assisted dissolution short peptide tag for improving recombinant protein expression efficiency | 济南宜明医疗科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230226122-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | SYNLOGIC OPERATING COMPANY, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230131339-A1 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | BADEN-WUERTTEMBERG STIFTUNG GGMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-11608331-B2 | Anti-SARS CoV-2 inhibitors by dual viral-host targeting | UNIVERSITY OF SHARJAH (AE) | 2023-03-21 | — | — | US | disclosed |
| EP-4110790-A2 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | Universität Ulm (DE) | 2023-01-04 | — | — | EP | disclosed |
| US-20220402905-A1 | Anti-SARS CoV-2 inhibitors by dual viral-host targeting | UNIVERSITY OF SHARJAH (AE) | 2022-12-22 | — | — | US | disclosed |
| WO-2022254388-A1 | DISCOVERY OF ANTI-SARS-COV-2 INHIBITORS BY DUAL VIRAL-HOST TARGETING | UNIVERSITY OF SHARJAH (AE) | 2022-12-08 | — | — | WO | disclosed |
| US-11471494-B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | SYNLOGIC OPERATING COMPANY, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402905-A1 | Anti-SARS CoV-2 inhibitors by dual viral-host targeting | ACE2, TMPRSS2, ACE | PTH1R 4671/4885GRPR 3093/4885CXCR4 572/4885 |
| US-11723932-B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | PDCD1, CD274, PDCD4 | PTH1R 2798/4885GRPR 1839/4885CXCR4 3326/4885 |
| US-11608331-B2 | Anti-SARS CoV-2 inhibitors by dual viral-host targeting | ACE2, TMPRSS2, ACE | PTH1R 4671/4885GRPR 3093/4885CXCR4 572/4885 |
| US-20230255981-A1 | THERAPEUTIC INHIBITION AFFINITY OF COPPER (II) COMPLEX AND THEIR DIAZENYL PYRIDINONE HETEROCYCLIC LIGANDS AGAINST SARS-COV2 | ACE2, C1QBP, ACE | PTH1R 3106/4885GRPR 4370/4885CXCR4 2531/4885 |
| US-20240226128-A1 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | TMPRSS2, ACE2, TMPRSS4 | PTH1R 3528/4885GRPR 2531/4885CXCR4 3507/4885 |
| US-11786537-B2 | Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2 | ACE2, C1QBP, ACE | PTH1R 3106/4885GRPR 4370/4885CXCR4 2531/4885 |
| US-20230131339-A1 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | CXCR4, SDF4, ACKR3 | PTH1R 1615/4885GRPR 1553/4885CXCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.